Latest ArticlesTo explore the effect of vedolizumab in the treatment of ulcerative colitis(UC) and its mechanism of action on mitochondrial autophagy.
A total of 96 patients with UC admitted to our hospital from January 2021 to December 2024 were selected as the research subjects. They were divided into the observation group and the control group by simple sorting random method, with 48 cases in each group. By the end of the study, the two groups had dropped to the observation group with 46 cases and the control group with 45 cases. The control group was treated with mesalazine enteric-coated tablets, while the observation group was added with vedolizumab. The treatment courses for both groups were 8 weeks. After treatment, the clinical efficacy, mitochondrial autophagy, inflammatory factors, intestinal mucosal barrier function and clinical symptom scores of the two groups were compared.
After treatment, the total effective rate of the observation group was higher than that of the control group(82.61% vs 62.22%, P<0.05). After treatment, the levels of PTEN-induced putative kinase(PINK)1 and parkinin in both groups were compared with those before treatment(P<0.05), and those in the observation group were higher than those in the control group(P<0.05). After treatment, the levels of tumor necrosis factor-α, interleukin(IL)-17 and IL-23 in both groups were lower than those before treatment(P<0.05), and those in the observation group were lower than those in the control group(P<0.05). After treatment, the levels of D-lactic acid, diamine oxidase and endothelin in both groups were lower than those before treatment(P<0.05), and those in the observation group were lower than those in the control group(P<0.05). By the end of the treatment, the scores of abdominal pain, diarrhea, mucus and bloody stool, and the total score in the observation group were all lower than those in the control group(P<0.05).
Vedilizumab treatment has a good effect on UC, which can increase the contents of PINK1 and paraquin in patients and reduce the levels of inflammatory factors.
To explore the clinical value of intravenous thrombolysis with alteplase in the treatment of wake-up stroke(WUS) within the tissue window.
Patients with WUS admitted to the neurology department of our hospital from July 2023 to January 2025 were selected and randomly divided into 3 groups, with 36 cases in each group. The control group(C group) received conventional drug treatment, the standard-dose group(B group) received intravenous thrombolysis with 0.9 mg/kg alteplase, and the low-dose group(A group) received intravenous thrombolysis with 0.6 mg/kg alteplase. The National Institutes of Health Stroke Scale(NIHSS) scores, clinical efficacy, bleeding status,coagulation function, platelet count(PLT), outcome status and adverse reactions of each group were compared.
At 24 hours, 7 days, 14 days and 30 days after treatment, the NIHSS scores of A and B group were lower than those of C group(P<0.05). The total effective rates of treatment in both A and B group were higher than that in C group(P<0.05). Before treatment and at 24 hours and 7 days after treatment, there were no significant differences in prothrombin time, activated partial thromboplastin time, fibrinogen and PLT levels among all groups(P>0.05). At 90 days after treatment, there were no significant differences in the rates of intracranial, digestive tract and urinary system, oral and skin and mucous membrane bleeding among all groups(P>0.05). The good outcome rate, modified Barthel index score and Montreal Cognitive Assessment Scale score of A and B group were all higher than those of C group(P<0.05). There was no significant difference in the total incidence of adverse drug reactions among all groups(P>0.05).
Intravenous thrombolysis with low-dose alteplase for intratuminal WUS can achieve a similar therapeutic effect to the standard dose, significantly improve neurological function, promote a good outcome, and have a relatively small impact on bleeding.
To explore the efficacy of rituximab as an adjuvant to GDP in the treatment of non-Hodgkin lymphoma(NHL) and its effect on thymidine kinase(TK)-1, recombinant factor related apoptosis ligand(FASL) and platelet-derived growth factor(PDGF)-BB.
A total of 210 NHL patients who were treated in our hospital from September 2021 to September 2024 were selected and randomly divided into the observation group and the control group,with 105 cases in each group. The control group was given the GDP regimen, while the observation group was added with rituximab. The clinical efficacy, TK-1, FASL, PDGF-BB, changes of peripheral blood T lymphocyte subsets, cluster of differentiation(CD)8+, CD4+ and CD3+ of the two groups were compared to evaluate the quality of life and occurrence of adverse reactions of the patients.
A total of 103 cases in the observation group and 101 cases in the control group completed the study. After treatment, the disease control rate of the observation group was higher than that of the control group(72.82% vs. 58.42%, P<0.05). The levels of TK-1, FASL and PDGF-BB in both groups were lower than those before treatment(P<0.05), and those in the observation group were lower than those in the control group(P<0.05). The CD8+ level in both groups was lower than that before treatment(P<0.05), and the level in the observation group was lower than that in the control group(P<0.05). The levels of CD4+ and CD3+ were increased before treatment, and the levels in the observation group were higher than those in the control group(P<0.05). The scores of physical function,emotional function, social function, cognitive function and role function of the two groups of patients were significantly higher, and the observation group was higher than the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups of patients(P>0.05).
Among NHL patients, the rituximab adjuvant GDP regimen has a better therapeutic effect and can effectively improve the levels of TK-1, FASL and PDGF-BB.
To explore the therapeutic effect of cinacalcet combined with renal failure mixture in chronic renal failure(CRF) with secondary hyperparathyroidism(SHPT) and its influence on fibroblast growth factor(FGF)-23,parathyroid hormone(PTH), and 25-hydroxyvitamin D3[25(OH)D3].
Patients with CRF accompanied by SHPT admitted to our hospital from January 2021 to December 2024 were selected for the study and randomly divided into the control group and the experimental group. All patients received hemodialysis treatment three times a week and were treated with calcium carbonate and renal failure mixture. The experimental group was given cinacalcet on the basis of the control group. The clinical efficacy, FGF-23, PTH, 25(OH)D3, blood calcium, blood phosphorus, calcium-phosphorus product, intact PTH(iPTH), thyroid volume and the occurrence of adverse reactions were compared between the two groups.
After treatment, the total clinical effective rate of the experimental group was higher than that of the control group(84.91% vs. 67.31%), and the difference was significant(P<0.05). The levels of FGF-23, PTH, 25(OH) D3, blood calcium, blood phosphorus, calcium-phosphorus product, iPTH and thyroid volume in the peripheral blood of the experimental group were all lower than those of the control group(P<0.05). During the treatment period, there was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05).
Cinacalcet combined with renal failure mixture as an adjuvant therapy for CRF with SHPT has a better effect and can help reduce the levels of FGF-23, PTH and 25(OH)D3 in the peripheral blood of patients.
To explore the effect of the Qingre Lishi Jiedu decoction formula as an adjunctive treatment for patients with perianal abscess, and to analyze its influence on inflammatory response and wound healing.
Patients with perianal abscess admitted to the anorectal department of our hospital from April 2023 to April 2024 were selected as the research subjects and randomly divided into the control group and the treatment group. Both groups underwent radical resection of perianal abscess. The control group was given potassium permanganate sitz bath combined with conventional anti-infection treatment after the operation, while the treatment group was also treated with fumigation and washing with the Qingre Lishi Jiedu decoction. The treatment course for both groups was 2 weeks. The clinical efficacy, traditional Chinese medicine(TCM) syndrome score, inflammatory factors, growth factors, wound healing indicators, anal function indicators and adverse reactions of the two groups were compared.
The total effective rate of the treatment group was higher than that of the control group(91.67% vs. 80.00%), and the difference was statistically significant(P<0.05).After treatment, the TCM syndrome score of the treatment group was lower than that of the control group(P<0.05)), the levels of serum inflammatory factors were all lower than those of the control group(P<0.05), and the level of growth factors was higher than that of the control group(P<0.05). The disappearance time of exudate, edema and wound healing time in the treatment group were shorter than those in the control group(P<0.05). The levels of wound healing indicators and anal function indicators in the treatment group were lower than those in the control group(P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups(P>0.05).
The Qingre Lishi Jiedu decoction can assist in alleviating the postoperative inflammatory response in patients with perianal abscess,promoting wound healing and the recovery of anal function.
To explore the effects of Ginkgo biloba leaves combined with Danlong Xingnao formula on cerebral blood flow, metabolism, and serum hypersensitive C-reactive protein(hs-CRP) and homocystine(Hcy) in elderly patients with vascular ischemic dementia.
A total of 110 elderly patients with vascular ischemic dementia in the First Affiliated Hospital of Naval Medical University from June 2020 to December 2022 were selected and divided into the observation group and the control group by simple sorting randomization, with 55 cases in each group. The control group was treated with donepezil, while the observation group was additionally treated with Ginkgo biloba leaves combined with Danlong Xingnao formula. The treatment outcomes and adverse reactions of the two groups were compared.
After treatment, the scores of the mini-mental state examination scale, Hasegawa dementia modified scale, the scores of the dementia pathological behavior assessment scale for behavioral function application and activities of daily living scale in the observation group were higher than those in the control group, while hemorheological indicators such as plasma viscosity, and the levels of serum hs-CRP and Hcy were lower than those in the control group(P<0.05). The improvement of anterior, middle and posterior arterial blood flow indicators(systolic blood flow velocity, diastolic blood flow velocity,mean blood flow velocity, pulsatile index) and brain metabolic indicators(choline/creatine ratio, lactic acid/creatine ratio)in the observation group was better than that in the control group(P<0.05). There was no significant difference in adverse reactions(P>0.05).
The combination of Ginkgo biloba leaves and Danlong Xingnao formula can improve the hemorheology, serum indicators, cerebral blood flow and metabolism of elderly patients, enhance cognitive and living abilities, and has good safety.
To explore the clinical study of tislelizumab combined with nab-paclitaxel and cisplatin(Nab-PP) for advanced lung squamous cell carcinoma with high expression of programmed death-ligand(PD-L)1.
The clinical data of patients with advanced lung squamous cell carcinoma with high PD-L1 expression who were admitted to our hospital from November 2020 to June 2023 were retrospectively collected. A total of 99 patients who received Nab-PP combined with tislelizumab treatment(the monoclonal antibody group), and 91 patients who received only Nab-PP treatment during the same period(the reference group) were initially included. The propensity score matching method was adopted, and the matching was carried out according to the 1∶1 ratio principle. Eventually, 52 patients in each group were successfully matched. The clinical efficacy, immune indicators, tumor markers, degree of primary lesion remission, functional status, quality of life scores, survival situation and safety between the two groups were compared.
The objective response rate of the monoclonal antibody group(55.77%) was higher than that of the reference group(32.69%, P<0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+ and natural killer cells in the monoclonal antibody group were all higher than those in the reference group, while the levels of squamous cell carcinoma antigen, carcinoembryonic antigen, cytokeratin 19 fragment and matrix metalloproteinase 9 were all lower than those in the reference group(P<0.05). In the monoclonal antibody group, there were 18 cases in stage Ⅲb. Among them, 16 cases(88.9%) eventually underwent radical surgery. Postoperative pathology confirmed 9 cases(56.3%) of major pathological response and 7 cases(43.8%) of pathological complete response. After the treatment, the Karnofsky performance status and the systematic evaluation of pulmonary function - lung score of the monoclonal antibody group were both higher than those of the reference group(P<0.05). The median progression-free survival and overall survival in the monoclonal antibody group were significantly higher than those in the reference group(χ2=13.882, 12.323, P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).
Tislelizumab combined with the Nab-PP regimen can significantly improve the clinical efficacy of patients with advanced lung squamous cell carcinoma with high PD-L1 expression, prolong survival time, and has a good safety profile. It is suitable for clinical promotion and application.
Peptide drugs, with their high activity, low dosage, few adverse reactions and strong specificity, have shown broad application prospects and potential. However, oral administration is easily destroyed and poorly absorbed. The conventional administration route of peptide drugs is injection, which has poor patient compliance. Nasal administration of peptide drugs can overcome the problems of low bioavailability of oral administration and poor compliance of injection administration, and provide a potential brain-targeted delivery route for some drugs(such as insulin). This article systematically reviewed the marketed nasal peptide preparations and analyzed their advantages in terms of administration convenience and patient compliance compared with injection dosage forms. At the same time, it reviewed the peptide nasal preparations in clinical and preclinical research and discussed strategies to improve the delivery efficiency of peptide drugs.
Premature ovarian failure is characterized by decreased ovarian function before the age of 40, which is mainly manifested by abnormal menstruation, increased gonadotropin, and fluctuating decline in estrogen levels. Based on the theory that "the kidney governs reproduction", traditional Chinese medicine, in combination with the syndrome differentiation of multiple organs such as the liver and spleen, often employs therapeutic methods such as soothing the liver and tonifying the kidney, strengthening the spleen and tonifying the kidney, and tonifying the kidney and promoting blood circulation. This article systematically reviewed the clinical research progress on the treatment of premature ovarian failure from the perspective of kidney therapy in the past three years, explored the therapeutic mechanisms and advantages of different treatment methods, and provided a reference for optimizing clinical treatment plans.
Adverse drug reactions (ADR) is a significant global public health concern, with notably increasing incidence rates and economic costs in China. Traditional ADR surveillance relying on spontaneous reporting systems suffers from delays and data incompleteness. The advancement of artificial intelligence (AI) technologies offers innovative solutions for ADR monitoring, enhancing efficiency and accuracy. This article reviewed the core technologies and current application status of AI, focusing on elucidating implementation scenarios and challenges in ADR early warning systems, aiming to provide references for AI-assisted ADR management strategies.